Design and Evaluation of Novel Tumor Cell-selective Anti-cancer Drugs Using Dimethyl-α-cyclodextrin
| Project/Area Number |
20890166
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (Start-up)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
MOTOYAMA Keiichi Kumamoto University, 大学院・生命科学研究部, 講師 (50515608)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥1,716,000 (Direct Cost: ¥1,320,000、Indirect Cost: ¥396,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥936,000 (Direct Cost: ¥720,000、Indirect Cost: ¥216,000)
|
|---|
| Keywords | 癌 / 薬学 / シクロデキストリン / DDS |
|---|
| Research Abstract |
In the present study, we prepared folate (FA)-appended methylated cyclodextrin (M-CyD) to evaluate that of cancer cell-selective cytotoxicity, because FA specifically binds to folate receptor (FR), which expresses in many cancer cells. FA-appended M-CyD entered into folate receptor (FR) over-expressing cancer cells and showed significant cytotoxicity. These results suggest may provide useful information when we prepare the novel anti-tumor agents using FA and M-CyD.
|
Report
(3 results)
Research Products
(4 results)
-
[Journal Article] Involvement of PI3K-Akt-Bad pathway in apoptosisinduced by 2, 6-di-O-methyl-8-cyclodextrin, not 2, 6-di-Omethyl-9-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells2009
Author(s)
Motoyama K, Kameyama K, Onodera R, Araki N, Hirayama F, Uekama K, Arima H
-
Journal Title
Eur. J. Pharm. Sci 38
Pages: 249-261
Related Report
Peer Reviewed
-
-
-
